The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Bregje VerhoevenDuring the 2nd European CAR T Cell Meeting in Sitges, ES, the Lymphoma Hub was delighted to speak to Bregje Verhoeven from European Society for Blood and Marrow Transplantation, NL. We asked: What impact does CAR T therapy have on patient quality of life?
Bregje Verhoeven explains that quality of life (QoL) after CAR T therapy is yet to be elucidated as we do not have enough data yet. She talks about the importance of implementing the patient-reported outcomes into clinical trials. Bregje Verhoeven also discusses the patient treatment teams and their role in improving patient QoL and various other factors such as emotional and financial burdens that influence the patients QoL.
What impact does CAR T therapy have on patient quality of life?